Global Opthalmic Therapeutic Market 2015-2019

眼科疾患治療薬の世界市場:緑内障、眼球乾燥症候群、網膜障害(糖尿病性網膜症、黄斑浮腫、RVO、AMD)

◆タイトル:Global Opthalmic Therapeutic Market 2015-2019
◆商品コード:IRTNTR6492
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年7月22日
◆ページ数:146
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、眼科疾患治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、眼科疾患治療薬の世界市場規模及び予測、眼科疾患別分析、投与経路(ROA)別分析、パイプライン分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Ophthalmic Diseases
Ophthalmology is the science of eyes. It is the branch of medicine concerned with the treatment of eye-related diseases and eye defects. Some of the common eye disorders are glaucoma, retinal diseases, conjunctivitis, refractive errors, color blindness, and retinitis. Many of the eye diseases do not show symptoms at early stages. They will be painless with no defect in vision until the disease progresses to an advanced stage. Regular eye checkups must be done to detect the development of any disorder. Proper care and hygiene must be ensured to protect the eyes.

Technavio’s analysts forecast the global ophthalmic therapeutic market to grow at a CAGR of 6.53% over the period 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the global ophthalmic therapeutic market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies, OTC drugs, and generics along with the drugs used as off-label for the treatment of ophthalmic disorders such as:
• Glaucoma
• Dry eye syndrome
• Retinal disorders such as diabetic retinopathy, macular edema, RVO, and AMD

Technavio’s report, Global Ophthalmic Therapeutic Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of global ophthalmic therapeutic market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Actavis
• Bayer
• F. Hoffmann-La Roche
• Merck
• Novartis
• Pfizer
• Regeneron Pharmaceuticals

[Other Prominent Vendors]
• Acadia Pharmaceuticals
• AC Immune
• Acorn Biomedical
• Acucela
• Advanced Cell Technology
• Aerie Pharmaceuticals
• Alcon
• Alexion Pharmaceuticals
• Alimera Sciences
• Allergan
• Ampio Pharmaceuticals
• Antisense Therapeutics
• Avalanche Biotechnologies
• BCN Peptides
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Carl Zeiss Meditec
• Eleven Biotherapeutics
• Falcon Pharmaceuticals
• Gilead Sciences
• GlaxoSmithKline
• Glycadia
• Icon Bioscience
• iCo Therapeutics
• Inotek Pharmaceuticals
• Intellect Neurosciences
• Isis Pharmaceuticals
• Kowa Group
• Laboratorios Sophia
• Lexicon Pharmaceuticals
• Lpath
• Neurotech Pharma
• NicOx
• Numoda Capital
• OPKO Health
• Ophthotech Corporation
• Ohr Pharmaceutical
• Otsuka Pharmaceutical
• PanOptica
• Parexel International
• Promedior
• pSivida
• Quark Pharmaceuticals
• R-Tech Ueno
• Santen Pharmaceutical
• Seikagaku
• Senju Pharmaceutical
• Shire
• SIFI
• Sirnaomics
• StemCells
• ThromboGenics
• Valeant Pharmaceuticals

[Market Driver]
• Increase in Prevalence of Eye Diseases
• For a full, detailed list, view our report

[Market Challenge]
• Lack of Awareness
• For a full, detailed list, view our report

[Market Trend]
• Strategic Alliances
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Glaucoma
06.1.1 Understanding the Disease
06.1.2 Types of Glaucoma
06.1.3 Etiology
06.1.4 Signs and Symptoms
06.1.5 Diagnosis
06.1.6 Management
06.1.7 Epidemiology
06.2 Dry Eye Syndrome
06.2.1 Understanding the Disease
06.2.2 Types of Dry Eye Syndrome
06.2.3 Causes of Dry Eye Syndrome
06.2.4 Risk Factors of Dry Eye Syndrome
06.2.5 Signs and Symptoms
06.2.6 Diagnosis
06.2.7 Management
06.3 Diabetic Retinopathy
06.3.1 Understanding the Disease
06.3.2 Etiology
06.3.3 Diagnosis
06.3.4 Classification
06.3.5 Epidemiology
06.3.6 Management
06.4 RVO
06.4.1 Understanding the Disease
06.4.2 Types of RVO
06.4.3 Etiology
06.4.4 Diagnosis
06.4.5 Management
06.5 AMD
06.5.1 Understanding the Disease
06.5.2 Stages of AMD
06.5.3 Types of AMD
06.5.4 Etiology
06.5.5 Signs and Symptoms
06.5.6 Diagnosis
06.5.7 Management
06.6 Macular Edema
06.6.1 Understanding the Disease
06.6.2 Etiology
06.6.3 Diagnosis
06.6.4 Management
06.7 Economic Burden of Ophthalmic Diseases

07.Pipeline Analysis
07.1 Pipeline Portfolio: Glaucoma
07.1.1 Rhopressa
07.1.2 Roclatan
07.1.3 Trabodenoson
07.1.4 Lomerizine HCl
07.1.5 Y-39983
07.2 Pipeline Portfolio: Dry Eye Syndrome
07.2.1 Lifitegrast
07.2.2 OPC-12759E
07.2.3 EBI-005
07.3 Pipeline Portfolio: Diabetic Retinopathy
07.3.1 Squalamine
07.3.2 K-115-R/Ripasudil Hydrochloride Hydrate
07.4 Pipeline Portfolio: AMD
07.4.1 Anecortave Acetate (Suspension)
07.4.2 E10030
07.4.3 Abicipar
07.5 Pipeline Portfolio: RVO
07.5.1 TLC399
07.5.2 AGN208397

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Disease Type
09.1 Global Ophthalmic Therapeutics Market by Disease Type
09.2 Glaucoma
09.3 Dry Eye Syndrome
09.4 Retinal Disorders
09.4.1 Diabetic Retinopathy
09.4.2 Macular Edema
09.4.3 AMD
09.4.4 RVO
09.5 Global Glaucoma Therapeutics Market
09.5.1 Market Size and Forecast
09.6 Global AMD Therapeutics Market
09.6.1 Market Size and Forecast
09.7 Global Macular Edema Therapeutics Market
09.7.1 Market Size and Forecast
09.8 Global Dry Eye Syndrome Therapeutics Market
09.8.1 Market Size and Forecast
09.9 Global Diabetic Retinopathy Therapeutics Market
09.9.1 Market Size and Forecast
09.10 Global RVO Therapeutics Market
09.10.1 Market Size and Forecast

10.Market Segmentation by Route of Administration
10.1 Topical
10.2 Systemic
10.2.1 IV
10.2.2 Oral
10.3 Intravitreal

11.Market Segmentation by Molecule Type
11.1 Biologics
11.2 Small Molecules

12.Market Segmentation by Dosage Form
12.1 Solutions
12.2 Implants
12.3 Pills

13.Geographical Segmentation
13.1 Global Ophthalmic Therapeutics Market by Geography 2014-2019

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and Their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and Their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Novartis
21.2.2 Actavis
21.2.3 F. Hoffmann-La Roche
21.2.4 Regeneron Pharmaceuticals
21.2.5 Bayer
21.2.6 Pfizer
21.2.7 Merck
21.3 Other and Future Prominent Vendors

22.Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Information
22.1.8 SWOT Analysis
22.2 Bayer
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2014
22.2.4 Business Segmentation by Revenue 2013 and 2014
22.2.5 Geographical Segmentation by Revenue 2014
22.2.6 Business Strategy
22.2.7 Recent Developments
22.2.8 SWOT Analysis
22.3 F. Hoffmann-La Roche
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Information
22.3.8 SWOT Analysis
22.4 Merck
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Novartis
22.5.1 Key Facts
22.5.2 Business Description
22.5.3 Business Segmentation
22.5.4 Revenue by Business Segmentation
22.5.5 Revenue Comparison 2012 and 2013
22.5.6 Sales by Geography
22.5.7 Business Strategy
22.5.8 Key Developments
22.5.9 SWOT Analysis
22.6 Pfizer
22.6.1 Key Facts
22.6.2 Business Overview
22.6.3 Business Segmentation by Revenue 2014
22.6.4 Business Segmentation by Revenue 2013 and 2014
22.6.5 Geographical Segmentation by Revenue 2014
22.6.6 Business Strategy
22.6.7 Key developments
22.6.8 SWOT Analysis
22.7 Regeneron Pharmaceuticals
22.7.1 Key Facts
22.7.2 Business Overview
22.7.3 Product Segmentation
22.7.4 Revenue Product Segmentation
22.7.5 Business Strategy
22.7.6 Key Information
22.7.7 SWOT Analysis

23.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Major Ophthalmic Conditions
Exhibit 3: Types of Glaucoma
Exhibit 4: Development of Diabetic Retinopathy
Exhibit 5: Classification of Diabetic Retinopathy
Exhibit 6: Types of RVO
Exhibit 7: Types of AMD
Exhibit 8: Global Ophthalmic Therapeutics Market 2014-2019 ($ millions)
Exhibit 9: Global Ophthalmic Therapeutics Market by Disease Type
Exhibit 10: Global Ophthalmic Therapeutics Market by Disease Type 2014
Exhibit 11: Global Glaucoma Therapeutics Market 2014-2019 ($ millions)
Exhibit 12: Key Takeaways: Global Glaucoma Therapeutics Market
Exhibit 13: Global AMD Therapeutics Market 2014-2019 ($ millions)
Exhibit 14: Key Takeaways: Global AMD Therapeutics Market
Exhibit 15: Global Macular Edema Therapeutics Market 2014-2019 ($ millions)
Exhibit 16: Key Takeaways: Global Macular Edema Therapeutics Market
Exhibit 17: Global Dry Eye Syndrome Therapeutics Market 2014-2019 ($ millions)
Exhibit 18: Key Takeaways: Global Dry Eye Syndrome Therapeutics Market
Exhibit 19: Global Diabetic Retinopathy Therapeutics Market 2014-2019 ($ millions)
Exhibit 20: Key Takeaways: Global Diabetic Retinopathy Therapeutics Market
Exhibit 21: Global RVO Therapeutics Market 2014-2019 ($ millions)
Exhibit 22: Key Takeaways: Global RVO Therapeutics Market
Exhibit 23: Global Ophthalmic Therapeutics Market: YoY Growth Rate and Revenue by Disease Type 2014-2019
Exhibit 24: Global Ophthalmic Therapeutics Market by Route of Administration
Exhibit 25: Global Ophthalmic Therapeutics Market by Molecule Type
Exhibit 26: Global Ophthalmic Therapeutics Market by Dosage Form
Exhibit 27: Global Ophthalmic Therapeutics Market by Geography 2014
Exhibit 28: Major Drivers of Global Ophthalmic Therapeutics Market
Exhibit 29: Major Challenges in Global Ophthalmic Therapeutics Market
Exhibit 30: Major Trends in Global Ophthalmic Therapeutics Market
Exhibit 31: Vendor Ranking 2014
Exhibit 32: Novartis: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
Exhibit 33: Actavis: YoY Revenue of Restasis 2012-2014 ($ millions)
Exhibit 34: Actavis: YoY Revenue of Lumigan 2012-2014 ($ millions)
Exhibit 35: Actavis: YoY Revenue of Alphagan, Alphagan P, and Combigan 2012-2014 ($ millions)
Exhibit 36: F. Hoffmann-La Roche: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
Exhibit 37: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate of Eylea 2011-2014 ($ millions)
Exhibit 38: Bayer: YoY Revenue and Growth Rate of Eylea 2012-2014 ($ millions)
Exhibit 39: Pfizer: YoY Revenue and Growth Rate of Xalatan/Xalacom 2012-2014 ($ millions)
Exhibit 40: Actavis: Business Segmentation 2013
Exhibit 41: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 42: Actavis: Sales by Geography ($ millions)
Exhibit 43: Bayer: Business Segmentation by Revenue 2014
Exhibit 44: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 45: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 46: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 47: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 48: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 49: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 50: Merck: Business Segmentation by Revenue 2013
Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 52: Merck: Sales by Geography 2013
Exhibit 53: Novartis: Business Segmentation
Exhibit 54: Novartis: Revenue by Business Segmentation 2013
Exhibit 55: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 56: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 57: Pfizer: Business Segmentation by Revenue 2014
Exhibit 58: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 59: Pfizer: Geographical Segmentation by Revenue 2014
Exhibit 60: Regeneron Pharmaceuticals: Product Segmentation
Exhibit 61: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013



【掲載企業】

Actavis, Bayer, F. Hoffmann-La Roche, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Acadia Pharmaceuticals, AC Immune, Acorn Biomedical, Acucela, Advanced Cell Technology, Aerie Pharmaceuticals, Alcon, Alexion Pharmaceuticals, Alimera Sciences, Allergan, Ampio Pharmaceuticals, Antisense Therapeutics, Avalanche Biotechnologies, BCN Peptides, Boehringer Ingelheim, Bristol-Myers Squibb, Carl Zeiss Meditec, Eleven Biotherapeutics, Falcon Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Glycadia, Icon Bioscience, iCo Therapeutics, Inotek Pharmaceuticals, Intellect Neurosciences, Isis Pharmaceuticals, Kowa Group, Laboratorios Sophia, Lexicon Pharmaceuticals, Lpath, Neurotech Pharma, NicOx, Numoda Capital, OPKO Health, Ophthotech Corporation, Ohr Pharmaceutical, Otsuka Pharmaceutical, PanOptica, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Santen Pharmaceutical, Seikagaku, Senju Pharmaceutical, Shire, SIFI, Sirnaomics, StemCells, ThromboGenics, Valeant Pharmaceuticals

【資料のキーワード】

眼科疾患治療薬、緑内障、眼球乾燥症候群、網膜障害、糖尿病性網膜症、黄斑浮腫、RVO、AMD、医薬品、眼科、治療、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[眼科疾患治療薬の世界市場:緑内障、眼球乾燥症候群、網膜障害(糖尿病性網膜症、黄斑浮腫、RVO、AMD)] (Global Opthalmic Therapeutic Market 2015-2019 / IRTNTR6492)販売に関する免責事項
[眼科疾患治療薬の世界市場:緑内障、眼球乾燥症候群、網膜障害(糖尿病性網膜症、黄斑浮腫、RVO、AMD)] (Global Opthalmic Therapeutic Market 2015-2019 / IRTNTR6492)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆